Science Explorer Back to mapMap

Most cited papers in Prostate Cancer Treatment and Research

Prostate Cancer Treatment and Research

What are the most cited papers in Prostate Cancer Treatment and Research?

The most cited paper in Prostate Cancer Treatment and Research is "Decision Curve Analysis: A Novel Method for Evaluating Prediction Models" (Andrew Julian Vickers, Elena B. Elkin, 2006), with 6,196 citations. Next come "Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" (5,779) and "Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer" (5,577).

Showing 50 of 100 papers. Every paper with more than 1,400 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Decision Curve Analysis: A Novel Method for Evaluating Prediction Models Andrew Julian Vickers, Elena B. Elkin · Medical Decision Making Open access Nov 2006 6,196
2 Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine 6 Oct 2004 5,779
3 Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine Open access 28 Jul 2010 5,577
4 Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Howard I. Scher, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine Open access 15 Aug 2012 4,645
5 Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer Anthony Victor D'Amico · JAMA 16 Sep 1998 4,551
6 Abiraterone and Increased Survival in Metastatic Prostate Cancer Johann Sebastian De Bono et al. · New England Journal of Medicine Open access 25 May 2011 4,448
7 Screening and Prostate-Cancer Mortality in a Randomized European Study Fritz H. Schröder et al. · New England Journal of Medicine Open access 18 Mar 2009 4,042
8 Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer Scott Arthur Tomlins, Daniel R. Rhodes, Sven Perner et al. · Science 27 Oct 2005 3,908
9 Integrative Genomic Profiling of Human Prostate Cancer Barry S. Taylor et al. · Cancer Cell Open access 25 Jun 2010 3,844
10 Integrative Clinical Genomics of Advanced Prostate Cancer Dan R. Robinson et al. · Cell Open access May 2015 3,727
11 Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer Daniel Peter Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine Open access 6 Oct 2004 3,706
12 Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer Chris C. Parker et al. · New England Journal of Medicine 17 Jul 2013 3,410
13 Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Johann Sebastian De Bono, Stéphane Marie. Oudard, Mustafa Özgüroğlu et al. · The Lancet Oct 2010 3,328
14 Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study Hashim Uddin Ahmed, Ahmed El‐Shater Bosaily, Louise Clare Brown et al. · The Lancet Open access 19 Jan 2017 3,318
15 The Molecular Taxonomy of Primary Prostate Cancer Adam A. Abeshouse et al. · Cell Open access312 authors Nov 2015 3,300
16 EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Nicolas Mottet et al. · European Urology Open access 31 Aug 2016 3,282
17 EAU Guidelines on Prostate Cancer Axel Heidenreich, Gunnar Aus, M. Bolla et al. · European Urology Open access 20 Sep 2007 3,150
18 Natural History of Progression After PSA Elevation Following Radical Prostatectomy Charles R. Pound · JAMA 5 May 1999 3,112
19 MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis Veeru Kasivisvanathan et al. · New England Journal of Medicine Open access 19 Mar 2018 3,101
20 Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Tomasz M. Beer et al. · New England Journal of Medicine Open access Jun 2014 3,076
21 PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2 Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke et al. · European Urology Open access 3 Oct 2015 2,978
22 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Christopher J. Sweeney, Yu‐Hui Chen, Michael Anthony Carducci et al. · New England Journal of Medicine Open access 5 Aug 2015 2,915
23 EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Nicolas Mottet et al. · European Urology Open access 7 Nov 2020 2,876
24 Epidemiology of Prostate Cancer Prashanth Rawla · World Journal of Oncology Open access 2019 2,838
25 Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Oliver A. Sartor, Johann Sebastian De Bono, Kim N. Chi et al. · New England Journal of Medicine Open access 23 Jun 2021 2,834
26 Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy Charles J. Ryan et al. · New England Journal of Medicine Open access 10 Dec 2012 2,827
27 Prospective Identification of Tumorigenic Prostate Cancer Stem Cells Anne T. Collins, Paul A. Berry, Catherine Hyde et al. · Cancer Research Dec 2005 2,826
28 Metastasis to bone: causes, consequences and therapeutic opportunities Gregory R. Mundy · Nature reviews. Cancer Review Aug 2002 2,802
29 The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Jonathan I Epstein, William C Allsbrook, Mahul B Amin et al. · The American Journal of Surgical Pathology 11 Aug 2005 2,785
30 Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Mack Roach, Gerald E. Hanks, Howard D. Thames et al. · International Journal of Radiation Oncology*Biology*Physics 24 Jun 2006 2,770
31 AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer Emmanuel S. Antonarakis et al. · New England Journal of Medicine Open access 3 Sep 2014 2,744
32 The polycomb group protein EZH2 is involved in progression of prostate cancer Sooryanarayana Varambally, Saravana Mohan Dhanasekaran, Ming Zhou et al. · Nature Open access Oct 2002 2,740
33 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer Freddie Charles Hamdy et al. · New England Journal of Medicine Open access 14 Sep 2016 2,672
34 The mutational landscape of lethal castration-resistant prostate cancer Catherine S. Grasso et al. · Nature Open access 18 May 2012 2,622
35 Gene expression correlates of clinical prostate cancer behavior Dinesh Rambachan Singh, Phillip G. Febbo, Kenneth N. Ross et al. · Cancer Cell Open access Mar 2002 2,542
36 Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement Virginia A. Moyer, on behalf of the U.S. Preventive Services Task Force* · Annals of Internal Medicine 17 Jul 2012 2,540
37 Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2 Barış Türkbey, Andrew B. Rosenkrantz, Masoom A. Haider et al. · European Urology 18 Mar 2019 2,528
38 The Influence of Finasteride on the Development of Prostate Cancer Ian Murchie Thompson, Phyllis J. Goodman, Catherine M. Tangen et al. · New England Journal of Medicine Open access 16 Jul 2003 2,523
39 ESUR prostate MR guidelines 2012 Jelle O. Barentsz, Jonathan Richenberg, Richard Clements et al. · European Radiology Open access 9 Feb 2012 2,452
40 Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter Ian Murchie Thompson, Donna K. Pauler, Phyllis J. Goodman et al. · New England Journal of Medicine 26 May 2004 2,448
41 Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment Susan K. Hobbs, Wayne L. Monsky, Fan Yuan et al. · Proceedings of the National Academy of Sciences Open access 14 Apr 1998 2,434
42 Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer William J. Catàlona, Deborah S. Smith, Timothy L. Ratliff et al. · New England Journal of Medicine 25 Apr 1991 2,403
43 Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer Chris Tran, Samedy Ouk, Nicola J. Clegg et al. · Science Open access 9 Apr 2009 2,341
44 The development of androgen-independent prostate cancer Brian J. Feldman, David I Feldman · Nature reviews. Cancer Review Oct 2001 2,338
45 Olaparib for Metastatic Castration-Resistant Prostate Cancer Johann Sebastian De Bono, Joaquı́n Mateo, Karim S. Fizazi et al. · New England Journal of Medicine Open access 28 Apr 2020 2,322
46 Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Karim S. Fizazi, NamPhuong Tran, Luis Enrique Fein et al. · New England Journal of Medicine Open access 4 Jun 2017 2,310
47 Molecular determinants of resistance to antiandrogen therapy Charlie D. Chen, Derek S. Welsbie, Chris Tran et al. · Nature Medicine 21 Dec 2003 2,291
48 Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology Open access 28 Feb 2008 2,267
49 DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Joaquı́n Mateo et al. · New England Journal of Medicine Open access 28 Oct 2015 2,220
50 Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer Johann Sebastian De Bono, Howard I. Scher, Bruce Montgomery et al. · Clinical Cancer Research 30 Sep 2008 2,205

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.